Atalanta, Barcelona and UEFA Champions League

Atalanta have outperformed their expectations in the Champions League this season and will now make one final push in their ...
The startup says its specially constructed RNAi therapies can get deep into brain tissue, yielding new ways to treat neurological conditions like Huntington’s.
The company, co-founded by Nobel Laureate Craig Mello, aims to push molecules for Huntington’s and a form of epilepsy into Phase I trials, with additional preclinical assets targeting Parkinson’s and ...
Atalanta Therapeutics is building on the growing attention around RNAi-based medicines with its $97 million Series B financing and plans to enter the clinic.
Ahead of the start of the FC Barcelona vs Atalanta UCL game, let's take a look at how to watch the match live. Get hold of ...
Ahead of Barcelona’s crucial home match against Atalanta in the UEFA Champions League, manager Hansi Flick faced the media to ...
Atalanta Therapeutics, a biotechnology company pioneering RNA interference (RNAi) for the treatment of neurological diseases, today announced the completion of a $97 million Series B financing to ...